Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT.


Journal

British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544

Informations de publication

Date de publication:
08 2020
Historique:
received: 13 11 2019
revised: 15 01 2020
accepted: 20 01 2020
pubmed: 29 2 2020
medline: 4 3 2021
entrez: 29 2 2020
Statut: ppublish

Résumé

Myeloproliferative Neoplasm (MPN), unclassifiable (MPN-U) is a heterogeneous disease with regards to both clinical phenotype and disease course. Patients may initially be asymptomatic or present with leucocytosis or thrombocytosis, anaemia, progressive splenomegaly, constitutional symptom, thromboses or accelerated/blastic phase disease. Treatment strategies are variable and there are no widely accepted consensus management guidelines for MNU-U. Allogeneic Haematopoietic Cell Transplantation (allo-HCT) remains the only curative strategy yet outcomes, to date, are not well defined. We hereby report on the largest retrospective study of patients with MPN-U undergoing allo-HCT, highlighting the potentially curative role and providing clinicians with robust engraftment, GvHD and outcome data to facilitate patient discussion.

Identifiants

pubmed: 32108327
doi: 10.1111/bjh.16537
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

437-441

Informations de copyright

© 2020 British Society for Haematology and John Wiley & Sons Ltd.

Références

Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., Bloomfield, C.D., Cazzola, M. & Vardiman, J.W. (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127, 2391-2405.
Bacigalupo, A., Ballen, K., Rizzo, D., Giralt, S., Lazarus, H., Ho, V., Apperley, J., Slavin, S., Pasquini, M., Sandmaier, B.M., Barrett, J., Blaise, D., Lowski, R. & Horowitz, M. (2009) Defining the intensity of conditioning regimens: Working definitions. Biology of Blood and Marrow Transplantation, 15, 1628-1633.
Gianelli, U., Cattaneo, D., Bossi, A., Cortinovis, I., Boiocchi, L., Liu, Y.C., Augello, C., Bonometti, A., Fiori, S., Orofino, N., Guidotti, F., Orazi, A. & Iurlo, A. (2017) The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations. Modern Pathology, 30, 169-179.
Hultcrantz, M., Kristinsson, S.Y., Andersson, T.M., Landgren, O., Eloranta, S., Derolf, A.R., Dickman, P.W. & Björkholm, M. (2012) Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. Journal of Clinical Oncology, 30, 2995-3001.
Iurlo, A., Gianelli, U., Cattaneo, D., Thiele, J. & Orazi, A. (2017) Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version. American Journal of Hematology, 92, E48-E51.
McLornan, D., Szydlo, R., Koster, L., Chalandon, Y., Robin, M., Wolschke, C., Beelen, D., Socié, G., Bornhäuser, M., Angelucci, E., Niederwieser, D., Gerbitz, A., Finke, J., Vitek, A., Itälä-Remes, M., Radujkovic, A., Kanz, L., Potter, V., Chevallier, P., Stelljes, M., Petersen, E., Robinson, S., Poiré, X., Klyuchnikov, E., Hernández-Boluda, J.C., Czerw, T., Hayden, P., Kröger, N. & Yakoub-Agha, I. (2019) Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant [Epub ahead of print].
Srour, S.A., Devesa, S.S., Morton, L.M., Check, D.P., Curtis, R.E., Linet, M.S. & Dores, G.M. (2016) Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12. British Journal of Haematology, 174, 382-396.

Auteurs

Donal P McLornan (DP)

Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.

Vittoria Malpassuti (V)

Dipartimento di Biologia, Università degli Studi di Roma Tor Vergata, Rome, Italy.

Anne Lippinkhof-Kozijn (A)

EBMT Data Office, Leiden, Netherlands.

Victoria Potter (V)

Department of Haematological Medicine, King's College Hospital, London, UK.

Dietrich Beelen (D)

Department of Bone Marrow Transplantation, West German Cancer Centre, University Hospital of Essen, University of Duisburg, Essen, Germany.

Donald Bunjes (D)

Universitätsklinikum Ulm, Ulm, Germany.

Henrik Sengeloev (H)

Department of Haematology, Rigshospitalet, Copenhagen, Denmark.

Aleksandar Radujkovic (A)

Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.

Jakob Passweg (J)

Department of Haematology, University Hospital, Basel, Switzerland.

Yves Chalandon (Y)

Hôpitaux Universitaires De Genève, Geneva, Switzerland.

Nicolaus Kröger (N)

University Hospital Eppendorf, Hamburg, Germany.

Gerald G Wulf (GG)

Universitätsklinikum Göttingen, Göttingen, Germany.

Jan-Erik Johansson (JE)

Sahlgrenska University Hospital, Göteborg, Sweden.

Fabio Ciceri (F)

Ospedale San Raffaele s.r.l, Milan, Italy.

Martin Bornhäuser (M)

Universitätsklinikum Dresden, Dresden, Germany.

Ernst Holler (E)

University of Regensburg, Regensburg, Germany.

Blandine Guffroy (B)

Nouvel Hôpital Civil, Strasbourg, France.

Sonja Martin (S)

Robert-Bosch-Krankenhaus, Stuttgart, Germany.

Andreas Neubauer (A)

Philipps Universität Marburg, Marburg, Germany.

Martin Gramatski (M)

University Medical Center Schleswig-Holstein, Kiel, Germany.

Marie Robin (M)

Service d'Hématologie-Greffe, Hôpital Saint-Louis, Paris, France.

Simona Iacobelli (S)

Dipartimento di Biologia, Università degli Studi di Roma Tor Vergata, Rome, Italy.

Patrick Hayden (P)

St. James's Hospital, Dublin, Ireland.

Juan C Hernández Boluda (JC)

Hospital Clínico Universitario de Valencia, Valencia, Spain.

Tomasz Czerw (T)

Maria Sklodowska-Curie Institute - Oncology Center, Gliwice Branch, Gliwice, Poland.

Ibrahim Yakoub-Agha (I)

Université de Lille, Inserm, CHU Lille. INSERM, Infinite, U1286, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH